{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:22:10Z","timestamp":1787556130279,"version":"build-2736575974"},"reference-count":67,"publisher":"National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)","issue":"2","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. oncol."],"abstract":"<jats:p>Recently, the identification of minimal residual disease (MRD), also known as measurable residual disease, has seen significant advances driven by the evolving technological landscape in this field. Initially based on raw morphology, the field has since evolved to incorporate karyotyping, cytogenetics, flow cytometry, and other sensitive methods. This updated review discusses key technical considerations for successful MRD detection. We explore the correlation between the results obtained by flow cytometry and molecular genetic techniques.<\/jats:p>","DOI":"10.15407\/exp-oncology.2026.02.098","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:00:07Z","timestamp":1787554807000},"page":"98-107","source":"Crossref","is-referenced-by-count":0,"title":["MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA: METHODS FOR DETECTION AND QUANTIFICATION"],"prefix":"10.15407","volume":"48","author":[{"given":"Sara","family":"Addakiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa","family":"Bencharef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Harrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiha","family":"Jaddaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Ait-Ichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Oukkache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"32237","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"17998","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revisionof the World Health Organization classification of lymphoidneoplasms. Blood. 2016;127(20):2375-2390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","DOI":"10.1182\/blood-2016-01-643569"},{"key":"17999","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursorleukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156. https:\/\/doi.org\/10.1016\/S1470-2045(08)70314-0","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"18000","doi-asserted-by":"crossref","unstructured":"Gaynon PS, Trigg ME, Heerema NA, et al. Children\u2019s Cancer Group trials in childhoodacute lymphoblastic leukemia: 1983\u20131995. Leukemia. 2000;14(12):2223-2233. https:\/\/doi.org\/10.1038\/sj.leu.2401939","DOI":"10.1038\/sj.leu.2401939"},{"key":"18001","doi-asserted-by":"crossref","unstructured":"Schultz KR, PullenDJ, Sather HN, et al. Risk- and response-based classification of childhoodB-precursor acute lymphoblastic leukemia: a combinedanalysis of prognostic markers from the PediatricOncology Group (POG) and Children\u2019sCancer Group (CCG). Blood. 2006;109(3):926-935. https:\/\/doi.org\/10.1182\/blood-2006-01-024729","DOI":"10.1182\/blood-2006-01-024729"},{"key":"18002","doi-asserted-by":"crossref","unstructured":"Hunger SP, Loh ML, WhitlockJA, et al. COG Acute Lymphoblastic Leukemia Committee. Children\u2019s OncologyGroup\u2019s 2013 blueprintfor research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957-963. https:\/\/doi.org\/10.1002\/pbc.24420","DOI":"10.1002\/pbc.24420"},{"key":"18003","doi-asserted-by":"crossref","unstructured":"Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616-3622. https:\/\/doi.org\/10.1200\/JCO.2003.10.116","DOI":"10.1200\/JCO.2003.10.116"},{"key":"18004","doi-asserted-by":"crossref","unstructured":"Wood BL, Winter SS, DunsmoreKP, et al. T-lymphoblastic Leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor(ETP) immunophenotype, and validation of the prognostic value of end-induction minimalresidual disease(MRD) in Children\u2019s OncologyGroup (COG) study AALL0434. Blood.2014;124(21):1.https:\/\/doi.org\/10.1182\/blood.V124.21.1.1","DOI":"10.1182\/blood.V124.21.1.1"},{"key":"18005","doi-asserted-by":"crossref","unstructured":"Smith M, Arthur D, Camitta B, et al. Uniformapproach to risk classification and treatment assignment for children withacute lymphoblastic leukemia.J ClinOncol. 1996;14(1):18-24. https:\/\/doi.org\/10.1200\/JCO.1996.14.1.18","DOI":"10.1200\/JCO.1996.14.1.18"},{"key":"18006","doi-asserted-by":"crossref","unstructured":"Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for childrenwith T cell acute lymphocyticleukemia (ALL), as comparedto those with B-precursor ALL. A Pediatric Oncology Group (POG)study. Leukemia. 1999;13(11):1696-1707. https:\/\/doi.org\/10.1038\/sj.leu.2401555","DOI":"10.1038\/sj.leu.2401555"},{"key":"18007","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Borleri G, Dotti G, et al. Innovativetwo-step negative selectionof granulocyte colony-stimulating factor\u2013mobilized circulating progenitor cells: Adequacy for autologous and allogeneic transplantation. Blood.1998;91(6):2189-2196.https:\/\/doi.org\/10.1182\/blood.V91.6.2189","DOI":"10.1182\/blood.V91.6.2189.2189_2189_2196"},{"key":"18008","doi-asserted-by":"crossref","unstructured":"Gaipa G, BassoG, Biondi A, et al. Detectionof minimal residualdisease in pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2013;84(6):359-369. https:\/\/doi.org\/10.1002\/cyto.b.21101","DOI":"10.1002\/cyto.b.21101"},{"key":"18009","doi-asserted-by":"crossref","unstructured":"Mancini M, Cedrone M, Diverio D, et al. Use of dual-color interphase FISH for the detectionof inv(16) in acute myeloid leukemiaat diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia.2000;14(3):364-368. https:\/\/doi.org\/10.1038\/sj.leu.2401678","DOI":"10.1038\/sj.leu.2401678"},{"key":"18010","doi-asserted-by":"crossref","unstructured":"Bielorai B, Golan H, Trakhtenbrot L, et al. Combined analysis of morphology and fluorescence in situ hybridiza- tion in follow-upof minimal residualdisease in a child with Philadelphia-positive acute lymphoblastic leukemia. Cancer GenetCytogenet. 2002;138(1):64-68. https:\/\/doi.org\/10.1016\/S0165-4608(02)00578-2","DOI":"10.1016\/S0165-4608(02)00578-2"},{"key":"18011","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimalresidual diseasein children with acute lymphoblastic leukaemia. Lancet. 1998;351(9102):550-554.https:\/\/doi.org\/10.1016\/S0140-6736(97)10295-1","DOI":"10.1016\/S0140-6736(97)10295-1"},{"key":"18012","doi-asserted-by":"crossref","unstructured":"Farahat N, Morilla A, Owusu-Ankomah K, et al. Detection of minimalresidual diseasein B-lineage acute lym- phoblastic leukaemia by quantitative flow cytometry. Br J Haematol. 1998;101(1):158-164. https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00675.x","DOI":"10.1046\/j.1365-2141.1998.00675.x"},{"key":"18013","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, et al. Clinicalimportance of minimalresidual diseasein childhood acute lymphoblasticleukemia. Blood. 2000;96(8):2691-2696. https:\/\/doi.org\/10.1182\/blood.V96.8.2691","DOI":"10.1182\/blood.V96.8.2691"},{"key":"18014","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Vidriales MB, L\u00f3pez-Berges C, et al. Early immunophenotypical evaluation of minimalresidual diseasein acute myeloidleukemia identifies different patientrisk groups and may contribute to postinduction treatment stratification. Blood. 2001;98(6):1746-1751. https:\/\/doi.org\/10.1182\/blood.V98.6.1746.","DOI":"10.1182\/blood.V98.6.1746"},{"key":"18015","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Fr\u00f6schl G, PrintzD, et al.; AustrianBerlin-Frankfurt-M\u00fcnster Study Group. Prognostic significance and modalities of flow cytometric minimal residualdisease detection in childhoodacute lymphoblastic leukemia. Blood. 2002;99(6):1952-1958. https:\/\/doi.org\/10.1182\/blood.V99.6.1952","DOI":"10.1182\/blood.V99.6.1952"},{"key":"18016","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemiccells by flow cytometryin childhood acute lymphoblastic leukemia. Blood. 2002;100(1):52-58. https:\/\/do.org\/10.1182\/blood-2002-01-0006","DOI":"10.1182\/blood-2002-01-0006"},{"key":"18017","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral bloodinstead of bone marrow to monitor residual diseasein children with acute lymphoblastic leukemia. Blood.2002;100(7):2399-2402. https:\/\/doi.org\/10.1182\/blood-2002-04-1130","DOI":"10.1182\/blood-2002-04-1130"},{"key":"18018","doi-asserted-by":"crossref","unstructured":"Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometryand polymerase chain reaction for comprehensive detection of minimalresidual diseasein childhood acute lymphoblastic leukemia. Leukemia.1999;13(8):1221-1226. https:\/\/doi.org\/10.1038\/sj.leu.2401459","DOI":"10.1038\/sj.leu.2401459"},{"key":"18019","doi-asserted-by":"crossref","unstructured":"Oelschl\u00e4gel U, Nowak R, Schaub A, et al. Shift ofaberrant antigen expression atrelapse orattreatment failure in acute leuke- mia. Cytometry.2000;42(4):247-253. https:\/\/doi.org\/10.1002\/1097-0320(20000815)42:4<247::AID-CYTO5>3.0.CO;2-V","DOI":"10.1002\/1097-0320(20000815)42:4<247::AID-CYTO5>3.0.CO;2-V"},{"key":"18020","doi-asserted-by":"crossref","unstructured":"Baer MR, Stewart CC, Dodge RK, et al. High frequencyof immunophenotype changes in acute myeloid leuke-mia at relapse:implications for residual diseasedetection (Cancer and LeukemiaGroup B Study 8361). Blood. 2001;97(11):3574-3580. https:\/\/doi.org\/10.1182\/blood.V97.11.3574","DOI":"10.1182\/blood.V97.11.3574"},{"key":"18021","doi-asserted-by":"crossref","unstructured":"Porwit-MacDonald A, Bj\u00f6rklund E, Lucio P, et al. BIOMED-1 concerted action report: Flow cytometric charac- terization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosisand follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia.2000;14(5):816-825.https:\/\/doi.org\/10.1038\/sj.leu.2401741","DOI":"10.1038\/sj.leu.2401741"},{"key":"18022","doi-asserted-by":"crossref","unstructured":"Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leu- kaemia. BestPract Res Clin Haematol.2002;15(1):1-19. https:\/\/doi.org\/10.1053\/beha.2002.0182","DOI":"10.1053\/beha.2002.0182"},{"key":"18023","unstructured":"Dworzak MN, Fritsch G, Fleischer C, et al. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol.1998;26(4):305-313. PMID: 9546313"},{"key":"18024","doi-asserted-by":"crossref","unstructured":"Ciudad J, San Miguel JF, L\u00f3pez-Berges MC, et al. Detectionof abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. Br J Haematol. 1999;104(4):695-705. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01236.x","DOI":"10.1046\/j.1365-2141.1999.01236.x"},{"key":"18025","doi-asserted-by":"crossref","unstructured":"Fuda F, Chen W. Minimal\/measurable residual disease detectionin acute leukemiasby multiparameter flow cyto- metry. Curr HematolMalig Rep. 2018;13(6):455-466. https:\/\/doi.org\/10.1007\/s11899-018-0479-1","DOI":"10.1007\/s11899-018-0479-1"},{"key":"18026","doi-asserted-by":"crossref","unstructured":"Lavabre-Bertrand T, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cyto- metry: I. CD10 expression. Cytometry. 1994;18(4):209-217. https:\/\/doi.org\/10.1002\/cyto.990180404","DOI":"10.1002\/cyto.990180404"},{"key":"18027","doi-asserted-by":"crossref","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103. https:\/\/doi.org\/10.1038\/leu.2017.29","DOI":"10.1038\/leu.2017.29"},{"key":"18028","doi-asserted-by":"crossref","unstructured":"Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometryfor highly sensitiveMRD measurements in B-cell acutelymphoblastic leukemia. Blood. 2017;129(3):347-357. https:\/\/doi.org\/10.1182\/blood-2016-07-726307","DOI":"10.1182\/blood-2016-07-726307"},{"key":"18029","doi-asserted-by":"crossref","unstructured":"Della Starza I, ChiarettiS, De Propris MS, et al. Minimal residual diseasein acute lymphoblastic leukemia: Techni- cal andclinical advances. Front Oncol.2019;9:726. https:\/\/doi.org\/10.3389\/fonc.2019.00726","DOI":"10.3389\/fonc.2019.00726"},{"key":"18030","doi-asserted-by":"crossref","unstructured":"Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometryfor highly sensitiveMRD measurements in B-cell acutelymphoblastic leukemia. Blood. 2017;129(3):347-357. https:\/\/doi.org\/10.1182\/blood-2016-07-726307","DOI":"10.1182\/blood-2016-07-726307"},{"key":"18031","doi-asserted-by":"crossref","unstructured":"Liu Z, Li Y, Shi C. Monitoring minimal\/measurable residual diseasein B-cell acute lymphoblastic leukemia by flow cytometryduring targeted therapy. Int J Hematol. 2021;113(3):337-343. https:\/\/doi.org\/10.1007\/s12185-021-03085-y","DOI":"10.1007\/s12185-021-03085-y"},{"key":"18032","doi-asserted-by":"crossref","unstructured":"Kruse A, Abdel-Azim N, Kim HN, et al. Minimalresidual disease detectionin acute lymphoblastic leukemia. Int JMol Sci. 2020;21(3):1054. https:\/\/doi.org\/10.3390\/ijms21031054","DOI":"10.3390\/ijms21031054"},{"key":"18033","doi-asserted-by":"crossref","unstructured":"Szczepa\u0144ski T, Beishuizen A, Pongers-Willemse MJ, etal. Cross-lineage T cell receptor gene rearrangements occurin more than ninetypercent of childhood precursor-Bacute lymphoblastic leukemias:Alternative PCR targets for detectionof minimal residual disease. Leukemia.1999;13(2):196-205. https:\/\/doi.org\/10.1038\/sj.leu.2401277","DOI":"10.1038\/sj.leu.2401277"},{"key":"18034","doi-asserted-by":"crossref","unstructured":"Langerak AW, Groenen PJTA, Br\u00fcggemann M, et al. EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspectedlymphoproliferations. Leukemia.2012;26(10):2159-2171. https:\/\/doi.org\/10.1038\/leu.2012.246","DOI":"10.1038\/leu.2012.246"},{"key":"18035","doi-asserted-by":"crossref","unstructured":"Langerak AW, Szczepa\u0144ski T, van der Burg M, et al. Heteroduplex PCR analysisof rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia.1997;11(12):2192-2199. https:\/\/doi.org\/10.1038\/sj.leu.2400887","DOI":"10.1038\/sj.leu.2400887"},{"key":"18036","doi-asserted-by":"crossref","unstructured":"Germano G, del Giudice L, PalatronS, et al. Clonality profile in relapsedprecursor-B-ALL children by GeneScanand sequencing analyses. Consequences on minimalresidual diseasemonitoring. Leukemia.2003;17(8):1573-1582. https:\/\/doi.org\/10.1038\/sj.leu.2403008","DOI":"10.1038\/sj.leu.2403008"},{"key":"18037","doi-asserted-by":"crossref","unstructured":"Verhagen O, Willemse MJ, Breunis WB, et al. Application of germline IGH probes in real-timequantitative PCR for the detection of minimal residualdisease in acute lymphoblastic leukemia. Leukemia.2000;14(8):1426-1435. https:\/\/doi.org\/10.1038\/sj.leu.2401801","DOI":"10.1038\/sj.leu.2401801"},{"key":"18038","doi-asserted-by":"crossref","unstructured":"van der Velden VH, CazzanigaG, Schrauder A, et al.; EuropeanStudy Group on MRD detectionin ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-timequantitative PCR data. Leukemia. 2007;21(4):604-611. https:\/\/doi.org\/10.1038\/sj.leu.2404586","DOI":"10.1038\/sj.leu.2404586"},{"key":"18039","doi-asserted-by":"crossref","unstructured":"van der Velden VH, NoordijkR, Brussee M, et al. Minimalresidual diseasediagnostics in acute lymphoblastic leukaemia: Impact of primer characteristics and size of junctional regions. Br J Haematol. 2014;164(3):451-453. https:\/\/doi.org\/10.1111\/bjh.12621","DOI":"10.1111\/bjh.12621"},{"key":"18040","doi-asserted-by":"crossref","unstructured":"Szczepa\u0144ski T, Velden VHJ van der, Raff T, et al. Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stabilityof clonal markers for monitoring of minimalresidual diseaseand reveals the occurrence of second T-ALL. Leukemia.2003;17(11):2149-2156. https:\/\/doi.org\/10.1038\/sj.leu.2403081","DOI":"10.1038\/sj.leu.2403081"},{"key":"18041","doi-asserted-by":"crossref","unstructured":"Szczepanski T, Willemse MJ, Brinkhof B, et al. Comparative analysis of Ig and TCR gene rearrangements at diagno- sis and at relapse of childhoodprecursor-B\u2013ALL provides improved strategies for selection of stable PCR targetsfor monitoring of minimal residual disease. Blood.2002;99(7):2315-2323. https:\/\/doi.org\/10.1182\/blood.v99.7.2315","DOI":"10.1182\/blood.V99.7.2315"},{"key":"18042","doi-asserted-by":"crossref","unstructured":"Pui CH, RellingMV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535-1548. https:\/\/doi.org\/10.1056\/NEJMra023001","DOI":"10.1056\/NEJMra023001"},{"key":"18043","doi-asserted-by":"crossref","unstructured":"Downing JR, Shannon KM. Acute leukemia:A pediatric perspective. Cancer Cell. 2002;2(6):437-445. https:\/\/doi.org\/10.1016\/S1535-6108(02)00211-8","DOI":"10.1016\/S1535-6108(02)00211-8"},{"key":"18044","doi-asserted-by":"crossref","unstructured":"Ajuba IC, Madu AJ, Okocha C, et al. Frequencyand clinical impact of ETV6\/RUNX1, AF4-MLL,and BCR\/ABL fusion genes on features of acute lymphoblastic leukemia at presentation. Niger J Clin Pract. 2016;19(2):237-241. https:\/\/doi.org\/10.4103\/1119-3077.164351","DOI":"10.4103\/1119-3077.164351"},{"key":"18045","doi-asserted-by":"crossref","unstructured":"Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012;4(134):134ra63. https:\/\/doi.org\/10.1126\/scitranslmed.3003656","DOI":"10.1126\/scitranslmed.3003656"},{"key":"18046","doi-asserted-by":"crossref","unstructured":"Wu D, Emerson RO, Sherwood A, et al. Detection of minimalresidual diseasein B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540-4548. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3231","DOI":"10.1158\/1078-0432.CCR-13-3231"},{"key":"18047","doi-asserted-by":"crossref","unstructured":"Wood B, Wu D, Crossley B, et al. Measurable residual diseasedetection by high-throughput sequencing improves risk stratificationfor pediatric B-ALL. Blood. 2018;131(12):1350-1359. https:\/\/doi.org\/10.1182\/blood-2017-09-806521","DOI":"10.1182\/blood-2017-09-806521"},{"key":"18048","doi-asserted-by":"crossref","unstructured":"Wood BL, Wu D, Kirsch IM, et al. Residualdisease monitoringby high throughputsequencing provides risk stratifi- cation in childhood B-ALL and identifies a novel subset of patientshaving poor outcome. Blood.2016;128(22):1086. https:\/\/doi.org\/10.1182\/blood.V128.22.1086.1086","DOI":"10.1182\/blood.V128.22.1086.1086"},{"key":"18049","doi-asserted-by":"crossref","unstructured":"Pulsipher MA, Carlson C, LangholzB, et al. IgH-V(D)JNGS-MRD measurement pre-and early post-allotrans- plant defines very low-and very high-riskALL patients. Blood. 2015;125(22):3501-3508. https:\/\/doi.org\/10.1182\/blood-2014-12-615757","DOI":"10.1182\/blood-2014-12-615757"},{"key":"18050","doi-asserted-by":"crossref","unstructured":"Kotrova M, Muzikova K, Mejstrikova E, et al. The predictive strength of next-generation sequencing MRD detec-tion for relapse compared with current methods in childhood ALL. Blood. 2015;126(8):1045-1047. https:\/\/doi.org\/10.1182\/blood-2015-07-655159","DOI":"10.1182\/blood-2015-07-655159"},{"key":"18051","doi-asserted-by":"crossref","unstructured":"Huggett JF, Whale A. Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem. 2013;59(12):1691-1693. https:\/\/doi.org\/10.1373\/clinchem.2013.214742","DOI":"10.1373\/clinchem.2013.214742"},{"key":"18052","doi-asserted-by":"crossref","unstructured":"Huggett JF, Cowen S, Foy CA.Considerations for digital PCR as an accuratemolecular diagnostic tool. Clin Chem. 2015;61(1):79-88. https:\/\/doi.org\/10.1373\/clinchem.2013.214742","DOI":"10.1373\/clinchem.2014.221366"},{"key":"18053","doi-asserted-by":"crossref","unstructured":"Reinert T, Sch\u00f8ler LV, Thomsen R, et al. Analysis of circulating tumour DNA tomonitor disease burden following colorectalcancer surgery. Gut. 2016;65(4):625-634. https:\/\/doi.org\/10.1136\/gutjnl-2014-308859","DOI":"10.1136\/gutjnl-2014-308859"},{"key":"18054","doi-asserted-by":"crossref","unstructured":"Waterhouse M, Follo M, PfeiferD, et al. Sensitive and accuratequantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digitalPCR. Ann Hematol. 2016;95(5):739-744. https:\/\/doi.org\/10.1007\/s00277-016-2623-0","DOI":"10.1007\/s00277-016-2623-0"},{"key":"18055","doi-asserted-by":"crossref","unstructured":"Della Starza I, De Novi LA, Elia L, et al. Optimizing molecular minimalresidual diseaseanalysis in adult acute lymphoblastic leukemia. Cancers.2023;15(2):374. https:\/\/doi.org\/10.3390\/cancers15020374","DOI":"10.3390\/cancers15020374"},{"key":"18056","unstructured":"Pecoraro S, BerbenG, Burns M, et al. Overview and recommendations for the application of digital PCR.Lux- embourg: Publications Office of the EuropeanUnion, ISBN 978-92-76-00180-5, Article115736. https:\/\/doi.org\/10.2760\/192883"},{"key":"18057","doi-asserted-by":"crossref","unstructured":"van der Velden VH, CazzanigaG, Schrauder A, et al.; EuropeanStudy Group on MRD detectionin ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-timequantitative PCR data. Leukemia. 2007;21:604-611. https:\/\/doi.org\/10.1038\/sj.leu.2404586","DOI":"10.1038\/sj.leu.2404586"},{"key":"18058","doi-asserted-by":"crossref","unstructured":"Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimalresidual diseasemonitoring in childrenwith ALL. Bone Marrow Transplant. 2008;42(3):187-196. https:\/\/doi.org\/10.1038\/bmt.2008","DOI":"10.1038\/bmt.2008.122"},{"key":"18059","doi-asserted-by":"crossref","unstructured":"van Dongen JJ, van der Velden VH, Br\u00fcggemann M, et al. Minimal residual disease diagnostics in acute lympho-blastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996-4009. https:\/\/doi.org\/10.1182\/blood-2015-03-580027","DOI":"10.1182\/blood-2015-03-580027"},{"key":"18060","doi-asserted-by":"crossref","unstructured":"Kotrova M, van der Velden VHJ, van DongenJJM, et al. Next-generation sequencing indicates false-positive MRD results and better predictsprognosis after SCT in patients with childhoodALL. Bone Marrow Transplant. 2017;52(7):962-968. https:\/\/doi.org\/10.1038\/bmt.2017.16","DOI":"10.1038\/bmt.2017.16"},{"key":"18061","doi-asserted-by":"crossref","unstructured":"Kotrova M, Muzikova K, Mejstrikova E, et al. The predictive strength of next-generation sequencing MRD detec-tion for relapse compared with current methods in childhood ALL. Blood. 2015;126(8):1045-1047. https:\/\/doi.org\/10.1182\/blood-2015-07-655159","DOI":"10.1182\/blood-2015-07-655159"},{"key":"18062","doi-asserted-by":"crossref","unstructured":"Eckert C, Flohr T, K\u00f6hler R, et al. Very early\/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in responseto initial and relapse treatment. Leukemia.2011;25(8):1305-1313.https:\/\/doi.org\/10.1038\/leu.2011.89","DOI":"10.1038\/leu.2011.89"},{"key":"18063","doi-asserted-by":"crossref","unstructured":"Ladetto M, Br\u00fcggemann M, MonitilloL, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual diseasedetection in B-cell disorders. Leukemia.2014;28(6):1299-1307. https:\/\/doi.org\/10.1038\/leu.2013.375","DOI":"10.1038\/leu.2013.375"},{"key":"18064","unstructured":"Submitted: September 10, 2025"}],"container-title":["Experimental Oncology"],"original-title":[],"link":[{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/640\/470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/640\/470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:00:21Z","timestamp":1787554821000},"score":1,"resource":{"primary":{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/view\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8,21]]}},"URL":"https:\/\/doi.org\/10.15407\/exp-oncology.2026.02.098","relation":{},"ISSN":["2312-8852","1812-9269"],"issn-type":[{"value":"2312-8852","type":"electronic"},{"value":"1812-9269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}